Compare · ABT vs MNPR
ABT vs MNPR
Side-by-side comparison of Abbott Laboratories (ABT) and Monopar Therapeutics Inc. (MNPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and MNPR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $194.62B, about 259.1x MNPR ($751.0M).
- Over the past year, ABT is down 15.9% and MNPR is up 220.7% - MNPR leads by 236.5 points.
- MNPR has been more active in the news (14 items in the past 4 weeks vs 11 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 15 for MNPR).
- Company
- Abbott Laboratories
- Monopar Therapeutics Inc.
- Price
- $110.55-1.67%
- $109.22-2.63%
- Market cap
- $194.62B
- $751.0M
- 1M return
- +4.56%
- +0.92%
- 1Y return
- -15.86%
- +220.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 11
- 14
- Recent ratings
- 25
- 15
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. It also has a collaboration agreement with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.
Latest ABT
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)
- Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
Latest MNPR
- Amendment: Director Tsuchimoto Kim R sold $455,567 worth of shares (4,090 units at $111.39) as part of a pre-agreed trading plan and exercised 4,090 shares at a strike of $22.04 (SEC Form 4)
- Amendment: Director Anderson Raymond exercised 3,142 shares at a strike of $30.00 and sold $351,835 worth of shares (3,142 units at $111.98) as part of a pre-agreed trading plan (SEC Form 4)
- Acting Chief Medical Officer Rioux Patrice exercised 1,380 shares at a strike of $0.01 and sold $111 worth of shares (1 units at $111.26) as part of a pre-agreed trading plan, increasing direct ownership by 37% to 5,065 units (SEC Form 4)
- Director Tsuchimoto Kim R sold $455,567 worth of shares (4,090 units at $111.39) as part of a pre-agreed trading plan, decreasing direct ownership by 36% to 7,396 units (SEC Form 4)
- Director Anderson Raymond sold $351,189 worth of shares (3,142 units at $111.77) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 23,751 units (SEC Form 4)
- SEC Form 144 filed by Monopar Therapeutics Inc.
- SEC Form 144 filed by Monopar Therapeutics Inc.
- SEC Form 144 filed by Monopar Therapeutics Inc.
- Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
- Monopar Therapeutics downgraded by Cantor Fitzgerald with a new price target